Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Status:
Recruiting
Trial end date:
2025-05-20
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib
and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID
regimen will be given up to 24 months and stopped for observation. We propose this
combination will improve the deep remission (≥VGPR) compared to single Zanubrutinib or IRD
regimen and can be a time-limited regimen which will reduce the life-time therapy and benefit
the patients.